PE20140979A1 - Variantes de fc silenciosas de los anticuerpos anti-cd40 - Google Patents

Variantes de fc silenciosas de los anticuerpos anti-cd40

Info

Publication number
PE20140979A1
PE20140979A1 PE2013001101A PE2013001101A PE20140979A1 PE 20140979 A1 PE20140979 A1 PE 20140979A1 PE 2013001101 A PE2013001101 A PE 2013001101A PE 2013001101 A PE2013001101 A PE 2013001101A PE 20140979 A1 PE20140979 A1 PE 20140979A1
Authority
PE
Peru
Prior art keywords
seq
amino acid
acid sequence
antibody
heavy chain
Prior art date
Application number
PE2013001101A
Other languages
English (en)
Inventor
Christoph Heusser
James Rush
Karen Vincent
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44925566&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20140979(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20140979A1 publication Critical patent/PE20140979A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70578—NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Rheumatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)

Abstract

SE REFIERE A UN ANTICUERPO AISLADO QUE COMPRENDE UNA PORCION DE ENLACE DE ANTIGENO DE UN ANTICUERPO DIRIGIDO CONTRA UN POLIPEPTIDO DE CD40 OBJETIVO ( SEQ ID NO: 28), CARACTERIZADO PORQUE SE ENLAZA AL POLIPEPTIDO DE CD40 CON UNA KD DE 10 Nm Y COMPRENDE UNA REGION FC DE IgG SILENCIOSA. DICHO ANTICUERPO SE SELECCIONA DEL GRUPO QUE COMPRENDE: I)ANTICUERPO mAb1 EL CUAL TIENE LA SECUENCIA DE AMINOACIDOS DE LA CADENA PESADA SEQ ID NO: 11 Y LA SECUENCIA DE AMINOACIDOS DE LA CADENA LIGERA SEQ ID NO: 12; II) EL ANTICUERPO mAb2 EL CUAL TIENE LA SECUENCIA DE AMINOACIDOS DE LA CADENA PESADA SEQ ID NO: 13 Y LA SECUENCIA DE AMINOACIDOS DE LA CADENA LIGERA SEQ ID NO: 14; y III) EL ANTICUERPO mAb3 EL CUAL TIENE LA SECUENCIA DE AMINOACIDOS DE LA CADENA PESADA SEQ ID NO: 15 Y LA SECUENCIA DE AMINOACIDOS DE LA CADENA LIGERA SEQ ID NO: 16. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. SIENDO UTIL PARA TRATAMIENTOS DE TRASTORNOS AUTOINMUNE Y TRASTORNOS INFLAMATORIOS.
PE2013001101A 2010-11-15 2011-11-14 Variantes de fc silenciosas de los anticuerpos anti-cd40 PE20140979A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US41356710P 2010-11-15 2010-11-15

Publications (1)

Publication Number Publication Date
PE20140979A1 true PE20140979A1 (es) 2014-08-09

Family

ID=44925566

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2013001101A PE20140979A1 (es) 2010-11-15 2011-11-14 Variantes de fc silenciosas de los anticuerpos anti-cd40

Country Status (38)

Country Link
US (8) US8828396B2 (es)
EP (4) EP3222636A1 (es)
JP (1) JP5782132B2 (es)
KR (1) KR101632775B1 (es)
CN (2) CN105949314B (es)
AR (2) AR083847A1 (es)
AU (1) AU2011331288B2 (es)
BR (1) BR112013011644B1 (es)
CA (1) CA2815921C (es)
CL (1) CL2013001124A1 (es)
CO (1) CO6801629A2 (es)
CR (1) CR20130222A (es)
CU (1) CU24057B1 (es)
CY (1) CY1119097T1 (es)
DK (2) DK3502138T3 (es)
EA (1) EA026133B1 (es)
ES (2) ES2911460T3 (es)
GT (1) GT201300128A (es)
HR (2) HRP20220413T1 (es)
HU (2) HUE034203T2 (es)
IL (1) IL225719A (es)
JO (1) JO3266B1 (es)
LT (2) LT2640749T (es)
MA (1) MA34654B1 (es)
MX (1) MX336633B (es)
MY (1) MY159316A (es)
NZ (1) NZ609549A (es)
PE (1) PE20140979A1 (es)
PL (2) PL2640749T3 (es)
PT (2) PT2640749T (es)
RS (2) RS63094B1 (es)
SG (1) SG189928A1 (es)
SI (2) SI2640749T1 (es)
TW (2) TWI608016B (es)
UA (1) UA112417C2 (es)
UY (2) UY33728A (es)
WO (1) WO2012065950A1 (es)
ZA (1) ZA201302532B (es)

Families Citing this family (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3153526T3 (da) 2008-01-31 2020-12-14 Inst Nat Sante Rech Med Antistoffer mod human cd39 og anvendelse deraf til inhibering af aktivitet af t-regulatoriske celler
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
WO2012111762A1 (ja) * 2011-02-17 2012-08-23 協和発酵キリン株式会社 抗ｃｄ４０抗体の高濃度製剤
CN106279401A (zh) 2011-03-11 2017-01-04 贝丝以色列女执事医疗中心 Cd40片段及其用途
MY165090A (en) 2011-04-21 2018-02-28 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40
SG194701A1 (en) 2011-04-29 2013-12-30 Apexigen Inc Anti-cd40 antibodies and methods of use
SG10201610288TA (en) 2011-10-13 2017-02-27 Bristol Myers Squibb Co Antibody polypeptides that antagonize cd40l
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
ES2879552T3 (es) 2012-10-30 2021-11-22 Apexigen Inc Anticuerpos anti-CD40 y métodos de uso
ES2701051T3 (es) 2013-03-15 2019-02-20 Novartis Ag Conjugados de anticuerpo-fármaco
US10435475B2 (en) 2014-03-07 2019-10-08 Bristol-Myers Squibb Company Method of using antibody polypeptides that antagonize CD40 to treat IBD
US10786578B2 (en) 2014-08-05 2020-09-29 Novartis Ag CKIT antibody drug conjugates
US9982045B2 (en) 2014-08-12 2018-05-29 Novartis Ag Anti-CDH6 antibody drug conjugates
CN106852149B (zh) 2014-10-10 2021-08-27 依奈特制药公司 Cd73阻断
WO2016094679A1 (en) 2014-12-10 2016-06-16 Regents Of The University Of Minnesota Genetically modified cells, tissues, and organs for treating disease
GB201501613D0 (en) * 2015-01-30 2015-03-18 Ucb Biopharma Sprl Treatment of autoimmune disorders with CD154 antibodies
EP3081942A1 (en) * 2015-04-17 2016-10-19 Roche Diagniostics GmbH Pressure transmission liquid for cellular analyzer, cellular analyzer and method for analyzing a liquid cellular sample
UY36692A (es) 2015-05-29 2016-12-30 Abbvie Inc Anticuerpos anti-cd40 y usos de los mismos
PL3307322T3 (pl) 2015-09-04 2021-07-05 Primatope Therapeutics Inc. Humanizowane przeciwciała anty-cd40 i ich zastosowania
CA2997263C (en) * 2015-09-08 2022-10-04 Theripion, Inc. Apoa-1 fusion polypeptides and related compositions and methods
US9862760B2 (en) 2015-09-16 2018-01-09 Novartis Ag Polyomavirus neutralizing antibodies
WO2017059196A2 (en) 2015-09-30 2017-04-06 Janssen Biotech, Inc. Antagonistic antibodies specifically binding human cd40 and methods of use
WO2017064043A1 (en) 2015-10-12 2017-04-20 Innate Pharma Cd73 blocking agents
AU2017204936B2 (en) 2016-02-10 2019-06-27 Novartis Ag Use of inhibitors of the activity or function of PI3K for the treatment of primary Sjogren's Syndrome
KR102398425B1 (ko) 2016-03-08 2022-05-16 이나뜨 파르마 에스.에이. Siglec 중화 항체
WO2017157948A1 (en) 2016-03-14 2017-09-21 Innate Pharma Anti-cd39 antibodies
RU2756236C2 (ru) 2016-06-20 2021-09-28 Кимаб Лимитед PD-L1 специфические антитела
WO2018065552A1 (en) 2016-10-06 2018-04-12 Innate Pharma Anti-cd39 antibodies
WO2018083080A2 (en) 2016-11-04 2018-05-11 Innate Pharma Nkp46 ligand
US20180206726A1 (en) 2016-12-07 2018-07-26 Progenity Inc. Gastrointestinal tract detection methods, devices and systems
EP3574016A2 (en) 2017-01-24 2019-12-04 Innate Pharma NKp46 BINDING AGENTS
EP3577138A1 (en) 2017-02-06 2019-12-11 Innate Pharma Immunomodulatory antibody drug conjugates binding to a human mica polypeptide
EP3596124A1 (en) 2017-03-16 2020-01-22 Innate Pharma Compositions and methods for treating cancer
EP3600233A4 (en) * 2017-03-26 2020-10-21 Stafford, Vivi, Robyn METHOD OF TREATMENT OF SKIN DISEASES OF THE EYELIDS
EP3600416B1 (en) 2017-03-30 2023-06-07 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
WO2018185618A1 (en) 2017-04-03 2018-10-11 Novartis Ag Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
JP2020521458A (ja) * 2017-05-25 2020-07-27 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ 改変ＩｇＧ１ Ｆｃドメインおよび該ドメインと抗ＣＤ４０ドメイン抗体の融合物
CN110621697B (zh) 2017-05-25 2023-06-27 百时美施贵宝公司 拮抗性cd40单克隆抗体及其用途
WO2018220100A1 (en) * 2017-06-02 2018-12-06 F. Hoffmann-La Roche Ag Administration routes for immune agonists
CA3066514A1 (en) 2017-07-10 2019-01-17 Innate Pharma Siglec-9-neutralizing antibodies
EP3652207A1 (en) 2017-07-10 2020-05-20 Innate Pharma Combination therapy using antibody to human siglec-9 and antibody to human nkg2a for treating cancer
EP3684813A1 (en) * 2017-09-19 2020-07-29 MAB Discovery GmbH Agonistic cd40 antibodies
BR112020008379A2 (pt) * 2017-11-03 2020-11-03 Novartis Ag anticorpos anti-cd40 para uso no tratamento de síndrome de sjögren
WO2019106578A2 (en) 2017-12-01 2019-06-06 Novartis Ag Polyomavirus neutralizing antibodies
WO2019198019A1 (en) * 2018-04-13 2019-10-17 Novartis Ag Anti-cd40 antibodies for use in prevention of graft rejection
IT201800004853A1 (it) 2018-04-24 2019-10-24 Metodi per trattare il cancro
US11932681B2 (en) 2018-05-31 2024-03-19 Novartis Ag Hepatitis B antibodies
CA3103629A1 (en) 2018-06-15 2019-12-19 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
MX2020012107A (es) 2018-06-18 2021-01-29 Innate Pharma Composiciones y procedimientos para el tratamiento del cancer.
US20230041197A1 (en) 2018-06-20 2023-02-09 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with an immunomodulator
US20230009902A1 (en) 2018-06-20 2023-01-12 Progenity, Inc. Treatment of a disease or condition in a tissue orginating from the endoderm
WO2020053742A2 (en) 2018-09-10 2020-03-19 Novartis Ag Anti-hla-hbv peptide antibodies
AR117091A1 (es) 2018-11-19 2021-07-07 Bristol Myers Squibb Co Anticuerpos monoclonales antagonistas contra cd40 y sus usos
WO2020106754A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Methods and devices for treating a disease with biotherapeutics
WO2020128863A1 (en) 2018-12-19 2020-06-25 Novartis Ag Anti-tnf-alpha antibodies
WO2020136145A2 (en) 2018-12-26 2020-07-02 Innate Pharma Leucocyte immunoglobulin-like receptor neutralizing antibodies
US20220098315A1 (en) 2019-01-11 2022-03-31 Novartis Ag Anti-cd40 antibodies for use in treatment of hidradenitis
KR20220002959A (ko) 2019-04-23 2022-01-07 이나뜨 파르마 에스.에이. Cd73 차단 항체
EP3962493A2 (en) 2019-05-03 2022-03-09 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity/level of irf or sting or of treating cancer, comprising the administration of a sting modulator and/or purinergic receptor modulator or postcellular signaling factor
KR20220007086A (ko) 2019-05-08 2022-01-18 노파르티스 아게 T1dm 및 췌도염의 치료에 사용하기 위한 항-cd40 항체
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
MX2021015160A (es) 2019-06-12 2022-03-17 Novartis Ag Anticuerpos de receptor de peptido natriuretico 1 y metodos de uso.
JP2022553493A (ja) 2019-09-11 2022-12-23 ノバルティス アーゲー 患者におけるヒトウイルス関連障害を予防するための方法
EP4031566A1 (en) 2019-09-18 2022-07-27 Novartis AG Nkg2d fusion proteins and uses thereof
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
BR112022017148A2 (pt) 2020-02-27 2022-11-08 Novartis Ag Métodos para produzir células que expressam receptor de antígeno quimérico
CA3184366A1 (en) 2020-06-29 2022-01-06 Darby Rye Schmidt Viruses engineered to promote thanotransmission and their use in treating cancer
JP2023537115A (ja) 2020-08-13 2023-08-30 イナート・ファルマ・ソシエテ・アノニム 抗ｃｄ７３抗体を使用する癌処置方法
KR20230048112A (ko) * 2020-08-21 2023-04-10 우시 바이올로직스 (상하이) 컴퍼니 리미티드 Cd40 효능성 항체 및 이의 사용 방법
MX2023002107A (es) 2020-08-21 2023-03-15 Novartis Ag Composiciones y metodos para la generacion in vivo de celulas que expresan car.
US20240002509A1 (en) 2020-11-06 2024-01-04 Novartis Ag ANTIBODY Fc VARIANTS
EP4259661A1 (en) 2020-12-14 2023-10-18 Novartis AG Reversal binding agents for anti-natriuretic peptide receptor 1 (npr1) antibodies and uses thereof
EP4313109A1 (en) 2021-03-31 2024-02-07 Flagship Pioneering Innovations V, Inc. Thanotransmission polypeptides and their use in treating cancer
KR20240026185A (ko) * 2021-06-28 2024-02-27 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 항-cd40 항체, 항원 결합 단편 및 이의 의학적 용도
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
TW202323521A (zh) 2021-08-20 2023-06-16 瑞士商諾華公司 製備表現嵌合抗原受體的細胞之方法
WO2023025248A1 (zh) 2021-08-26 2023-03-02 映恩生物制药（苏州）有限公司 一种甾体化合物及其缀合物
WO2023044048A1 (en) 2021-09-17 2023-03-23 Novartis Ag Methods for prevention of graft rejection in xenotransplantation
AU2022350419A1 (en) 2021-09-24 2024-05-02 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Anti-cd40 antibody and use thereof
AU2022358474A1 (en) 2021-10-01 2024-03-28 Mab Discovery Gmbh Agonistic cd40 antibodies as immune stimulatory agents
WO2023187657A1 (en) 2022-03-30 2023-10-05 Novartis Ag Methods of treating disorders using anti-natriuretic peptide receptor 1 (npr1) antibodies
WO2024056809A1 (en) 2022-09-15 2024-03-21 Novartis Ag Treatment of autoimmune disorders using chimeric antigen receptor therapy
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024107752A2 (en) 2022-11-15 2024-05-23 Onestone Therapeutics Llc Compositions and methods for immunomodulatory bifunctional fusion molecules

Family Cites Families (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4766A (en) 1846-09-19 Stbaw-cutter
US106A (en) 1915-08-24 Specipication
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
DE3380726D1 (en) 1982-06-24 1989-11-23 Japan Chem Res Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
CA1292686C (en) 1986-10-27 1991-12-03 Ze'ev Shaked Pharmaceutical compositions of recombinant interleukin-2 and formulation process
CA1294215C (en) 1986-10-27 1992-01-14 Ze'ev Shaked Pharmaceutical compositions of recombinant beta-interferon and formulation processes
US5013653A (en) 1987-03-20 1991-05-07 Creative Biomolecules, Inc. Product and process for introduction of a hinge region into a fusion protein to facilitate cleavage
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
ATE243754T1 (de) 1987-05-21 2003-07-15 Micromet Ag Multifunktionelle proteine mit vorbestimmter zielsetzung
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5397703A (en) 1992-07-09 1995-03-14 Cetus Oncology Corporation Method for generation of antibodies to cell surface molecules
US5874082A (en) 1992-07-09 1999-02-23 Chiron Corporation Humanized anti-CD40 monoclonal antibodies and fragments capable of blocking B cell proliferation
DE69433406T2 (de) 1993-10-01 2004-10-07 Immunex Corp Antikörper gegen cd40
NZ278740A (en) 1993-12-23 1998-05-27 Immunex Corp Treating disease characterised by neoplastic cells expressing cd40 using a cd40 binding protein
EP0750458B1 (en) 1994-03-03 2003-08-27 Alexion Pharmaceuticals, Inc. Terminal complement inhibitor fusion genes and proteins
GB9425060D0 (en) 1994-12-13 1995-02-08 Univ Birmingham Carcinoma treatment
BR9609743A (pt) 1995-07-27 1999-03-02 Genentech Inc Formulação reconstituída estável método para a preparação de uma formulação artigo manufaturado e uso da formação
ES2190087T3 (es) 1997-06-13 2003-07-16 Genentech Inc Formulacion estabilizada de un anticuerpo.
CN1261285A (zh) 1997-06-20 2000-07-26 拜奥根有限公司 治疗性蛋白抑制剂综合症的cd154阻断治疗
EP1224940B2 (de) 1997-09-23 2010-08-11 Rentschler Biotechnologie GmbH Flüssige Interferon-Beta Formulierungen
US6051228A (en) 1998-02-19 2000-04-18 Bristol-Myers Squibb Co. Antibodies against human CD40
US20020006901A1 (en) 1999-02-05 2002-01-17 Aldo T. Iacono Use of aerosolized cyclosporine for prevention and treatment of pulmonary disease
WO2002004021A1 (en) 2000-07-12 2002-01-17 Idec Pharmaceuticals Corporation Treatment of b cell malignancies using combination of b cell depleting antibody and immune modulating antibody related applications
WO2001034649A2 (en) 1999-11-09 2001-05-17 Chiron Corporation Compositions and methods for treating autoimmune diseases and transplant rejections
US20030059427A1 (en) 2000-04-28 2003-03-27 Force Walker R. Isolation and characterization of highly active anti-CD40 antibody
US7063845B2 (en) 2000-04-28 2006-06-20 Gemini Science, Inc. Human anti-CD40 antibodies
WO2001083755A2 (en) 2000-04-28 2001-11-08 La Jolla Institute For Allergy And Immunology Human anti-cd40 antibodies and methods of making and using same
CA2422076A1 (en) 2000-09-18 2002-03-21 Idec Pharmaceutical Corporation Combination therapy for treatment of autoimmune diseases using b cell depleting/immunoregulatory antibody combination
WO2002028480A2 (en) 2000-10-02 2002-04-11 Chiron Corporation Methods of therapy for b-cell malignancies
JP4463475B2 (ja) 2001-01-31 2010-05-19 バイオジェン アイデック インコーポレイテッド 腫瘍疾患の治療における免疫調節性抗体の使用
ATE507839T1 (de) 2001-04-02 2011-05-15 Genentech Inc Kombinationstherapie
EP2009027B1 (en) 2001-04-27 2014-05-21 Kyowa Hakko Kirin Co., Ltd. Anti-CD40 monoclonal antibody
WO2003029296A1 (en) 2001-10-02 2003-04-10 Chiron Corporation Human anti-cd40 antibodies
AR039067A1 (es) * 2001-11-09 2005-02-09 Pfizer Prod Inc Anticuerpos para cd40
AU2002346581A1 (en) 2001-11-26 2003-06-10 Chiron Corporation Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
US20040110226A1 (en) * 2002-03-01 2004-06-10 Xencor Antibody optimization
US20080199471A1 (en) * 2002-03-01 2008-08-21 Bernett Matthew J Optimized cd40 antibodies and methods of using the same
DK2236154T3 (en) 2003-02-10 2018-06-25 Biogen Ma Inc IMMUNOGLOBULIN INFORMATION AND METHOD OF PREPARING IT
PT1680141E (pt) 2003-11-04 2010-12-20 Novartis Vaccines & Diagnostic Métodos terapêuticos para tumores sólidos que expressam o antigénio de superfície celular cd40
PT1682177E (pt) 2003-11-04 2010-11-29 Xoma Technology Lt Utilização de anticorpos antagonistas anti-cd40 para o tratamento da leucemia linfocítica crónica
EP2243492A1 (en) 2003-11-04 2010-10-27 Novartis Vaccines and Diagnostics, Inc. Use of antagonist anti-cd40 monoclonal antibodies for treatment of multiple myeloma
EP1682178B8 (en) 2003-11-04 2010-09-01 Novartis Vaccines and Diagnostics, Inc. Methods of therapy for cancers expressing the cd40 antigen
CA2544368C (en) 2003-11-04 2014-04-01 Chiron Corporation Methods of therapy for b cell-related cancers
US8277810B2 (en) 2003-11-04 2012-10-02 Novartis Vaccines & Diagnostics, Inc. Antagonist anti-CD40 antibodies
DK1707627T3 (da) * 2003-12-25 2012-12-17 Kyowa Hakko Kirin Co Ltd Antagonistisk anti-CD40-antistofmutant.
WO2006073443A2 (en) 2004-04-27 2006-07-13 Novartis Vaccines And Diagnostics, Inc. Antagonist anti-cd40 monoclonal antibodies and methods for their use
US20080057070A1 (en) * 2004-11-04 2008-03-06 Chiron Corporation Antagonist Anti-Cd40 Monoclonal Antibodies and Methods for Their Use
WO2006125117A2 (en) 2005-05-18 2006-11-23 Novartis Ag Methods for diagnosis and treatment of diseases having an autoimmune and/or inflammatory component
WO2007053661A2 (en) 2005-11-01 2007-05-10 Novartis Ag Uses of anti-cd40 antibodies
AR057253A1 (es) * 2005-12-16 2007-11-21 Genentech Inc Anticuerpos anti-ox40l y metodos que los utilizan
NZ571757A (en) 2006-04-21 2012-01-12 Novartis Ag Antagonist anti-CD40 antibody pharmaceutical compositions comprising arginine-HCl and a citrate or citric acid buffer
EP1854810A1 (en) 2006-05-09 2007-11-14 PanGenetics B.V. Deimmunized antagonistic anti-human CD40 monoclonal antibody from the ch5D12 antibody
WO2008060705A2 (en) * 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
EP2137325A1 (en) * 2007-04-02 2009-12-30 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
SI2550972T1 (en) * 2007-04-02 2018-05-31 Genentech, Inc. An antibody called Klotho-beta agonist for use in the treatment of diabetes mellitus or insulin resistance
DK2176298T3 (en) * 2007-05-30 2018-02-12 Xencor Inc Methods and compositions for inhibiting CD32B-expressing cells
KR20210060670A (ko) * 2008-12-09 2021-05-26 제넨테크, 인크. 항-ｐｄ-ｌ１ 항체 및 ｔ 세포 기능을 향상시키기 위한 그의 용도
PL2423228T3 (pl) * 2009-04-20 2016-06-30 Kyowa Hakko Kirin Co Ltd Przeciwciało zawierające IGG2 mającą wprowadzoną do niej mutację aminokwasową
AR083847A1 (es) * 2010-11-15 2013-03-27 Novartis Ag Variantes de fc (fragmento constante) silenciosas de los anticuerpos anti-cd40
US20140004131A1 (en) 2012-05-04 2014-01-02 Novartis Ag Antibody formulation
EP2967348B1 (en) 2013-03-15 2022-03-23 Synaptive Medical Inc. Intelligent positioning system

Also Published As

Publication number Publication date
US20160152721A1 (en) 2016-06-02
DK3502138T3 (da) 2022-04-19
US20240132606A1 (en) 2024-04-25
AR122999A2 (es) 2022-10-19
EP3222636A1 (en) 2017-09-27
CU24057B1 (es) 2014-12-26
MY159316A (en) 2016-12-30
IL225719A (en) 2017-09-28
US10323096B2 (en) 2019-06-18
US20200087409A1 (en) 2020-03-19
JP2014500720A (ja) 2014-01-16
US9688768B2 (en) 2017-06-27
ZA201302532B (en) 2014-09-25
CN103209996A (zh) 2013-07-17
PL3502138T3 (pl) 2022-05-02
UY39292A (es) 2021-07-30
GT201300128A (es) 2015-06-02
CN105949314A (zh) 2016-09-21
US20170267772A1 (en) 2017-09-21
EP4023676A1 (en) 2022-07-06
MX336633B (es) 2016-01-26
MA34654B1 (fr) 2013-11-02
DK2640749T3 (en) 2017-07-31
KR101632775B1 (ko) 2016-06-22
LT2640749T (lt) 2017-07-10
US20220204635A1 (en) 2022-06-30
CR20130222A (es) 2013-06-28
LT3502138T (lt) 2022-04-11
US20140341898A1 (en) 2014-11-20
SG189928A1 (en) 2013-06-28
KR20130080856A (ko) 2013-07-15
EP2640749B1 (en) 2017-04-19
US9221913B2 (en) 2015-12-29
ES2911460T3 (es) 2022-05-19
CO6801629A2 (es) 2013-11-29
BR112013011644A2 (pt) 2016-08-02
WO2012065950A1 (en) 2012-05-24
CY1119097T1 (el) 2018-01-10
TW201623335A (zh) 2016-07-01
EP2640749A1 (en) 2013-09-25
HUE058015T2 (hu) 2022-06-28
CN103209996B (zh) 2016-07-20
EP3502138B1 (en) 2022-01-19
RS56153B1 (sr) 2017-11-30
ES2633817T3 (es) 2017-09-25
HRP20171084T1 (hr) 2017-10-06
BR112013011644B1 (pt) 2022-02-22
CL2013001124A1 (es) 2014-07-04
PT2640749T (pt) 2017-07-25
IL225719A0 (en) 2013-06-27
US20180118843A1 (en) 2018-05-03
SI2640749T1 (sl) 2017-07-31
EA201390725A1 (ru) 2013-09-30
SI3502138T1 (sl) 2022-05-31
UY33728A (es) 2012-06-29
TWI531581B (zh) 2016-05-01
NZ609549A (en) 2015-05-29
TWI608016B (zh) 2017-12-11
HUE034203T2 (en) 2018-01-29
CN105949314B (zh) 2021-04-09
TW201305208A (zh) 2013-02-01
MX2013005477A (es) 2013-06-12
HRP20220413T1 (hr) 2022-05-27
US20120121585A1 (en) 2012-05-17
PL2640749T3 (pl) 2017-09-29
EP3502138A1 (en) 2019-06-26
CU20130071A7 (es) 2013-09-27
US8828396B2 (en) 2014-09-09
AU2011331288B2 (en) 2014-09-11
PT3502138T (pt) 2022-04-06
US11124578B2 (en) 2021-09-21
US9828433B2 (en) 2017-11-28
EP3502138B9 (en) 2022-03-09
UA112417C2 (uk) 2016-09-12
CA2815921C (en) 2021-07-06
AU2011331288A1 (en) 2013-05-02
JO3266B1 (ar) 2018-09-16
CA2815921A1 (en) 2012-05-24
EA026133B1 (ru) 2017-03-31
JP5782132B2 (ja) 2015-09-24
AR083847A1 (es) 2013-03-27
RS63094B1 (sr) 2022-04-29

Similar Documents

Publication Publication Date Title
PE20140979A1 (es) Variantes de fc silenciosas de los anticuerpos anti-cd40
PE20141162A1 (es) Anticuerpos anti-il-23
PE20130817A1 (es) Anticuerpos peptidicos beta amiloide anti-n3pglu y usos de los mismos
PE20141147A1 (es) Anticuerpos a pcsk9 y usos de los mismos
PE20142170A1 (es) Anticuerpos frente a los ligandos del receptor b1 de bradicinina
PE20191408A1 (es) Proteinas de union a antigeno st2
PE20141028A1 (es) Nuevos moduladores y metodos para su uso
ES2584956T3 (es) Anticuerpos anti-CD40 y usos de los mismos
ES2621874T3 (es) Anticuerpos para MUC16 y métodos de uso de los mismos
AR073978A1 (es) Anticuerpos humanos de alta afinidad para el receptor il-4-humano
PE20131403A1 (es) Anticuerpos anti-ox40 y metodos de uso de los mismos
PE20200294A1 (es) Anticuerpos que se unen especificamente a pd-1 y metodos de uso
PE20141659A1 (es) Dominios variables singulares anti-vgf fusionados con dominios de fc
PE20141937A1 (es) Metodos para tratar trastornos relacionados con mutante viii de eliminacion de factor de crecimiento epidermico
CO6230999A2 (es) Anticuerpo anti-esclerostina
AR079336A1 (es) Antagonistas de la pro-proteina convertasa-subtilisina/quexina tipo 9 (pcsk9)
PE20141151A1 (es) Proteinas de union al antigeno cd27l
ES2687282T3 (es) Anticuerpos humanizados ANTI-CD134 (OX40) y sus usos
NZ603226A (en) Anti-c5a antibodies and methods for using the antibodies
AR094271A1 (es) Anticuerpos anti-gdf15
PE20120340A1 (es) Combinaciones antitumorales que contienen anticuerpos que reconocen especificamente cd38 y melfalan
PE20140247A1 (es) Anticuerpos anti-cd38
PE20141166A1 (es) Anticuerpos anti-angptl3 y usos de los mismos
PE20120427A1 (es) Anticuerpos contra el receptor de cgrp humano
AR074563A1 (es) Anticuerpos anti ligando 1 de muerte programada (anti-pd-l1) y su uso para mejorar la funcion de las celulas t

Legal Events

Date Code Title Description
FG Grant, registration